Namir Hassan has been promoted to chief executive officer at Zelluna Immunotherapy AS from the position of chief scientific officer following the departure of Miguel Forte to head Bone Therapeutics SA. Dr Hassan was previously CSO of Immunocore Ltd where he was responsible for building the company’s infrastructure in oncology and led its first human trial in metastatic melanoma. Dr Hassan received a DPhil from the University of Oxford, UK in T cell biology.
Zelluna Immunotherapy announced the appointment on 19 December 2019.
Copyright 2020 Evernow Publishing Ltd